Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Swedbank AB

Key Points

• Swedbank AB increased its stake in Neurocrine Biosciences by 6.7% in Q4, buying 36,800 shares to hold 584,129 shares worth about $82.85 million (≈0.59% ownership).
• Institutional ownership is very high at 92.59%, with major funds (JPMorgan, AQR, UBS, Pictet, Deerfield) materially increasing positions, signaling strong institutional interest.
• Fundamentals are mixed: Q1 revenue of $805.5M beat estimates and rose 28.3% YoY while EPS of $1.88 missed consensus, yet analysts have raised targets and the stock carries a consensus "Moderate Buy" with an average target of $183.00.

Swedbank AB boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 584,129 shares of the company's stock after purchasing an additional 36,800 shares during the quarter. Swedbank AB owned about 0.59% of Neurocrine Biosciences worth $82,847,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its stake in shares of Neurocrine Biosciences by 11.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company's stock valued at $664,019,000 after buying an additional 468,405 shares during the period. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company's stock valued at $388,435,000 after acquiring an additional 1,263,633 shares during the period. Deerfield Management Company L.P. increased its stake in Neurocrine Biosciences by 1.4% during the third quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company's stock worth $166,258,000 after acquiring an additional 16,543 shares during the last quarter. UBS Group AG raised its holdings in shares of Neurocrine Biosciences by 169.8% in the 4th quarter. UBS Group AG now owns 983,528 shares of the company's stock worth $139,494,000 after purchasing an additional 618,956 shares during the period. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Neurocrine Biosciences by 12.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 776,934 shares of the company's stock valued at $110,305,000 after purchasing an additional 83,488 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $147.02 on Thursday. The firm has a fifty day moving average of $130.75 and a two-hundred day moving average of $137.79. The firm has a market cap of $14.79 billion, a P/E ratio of 22.65, a P/E/G ratio of 0.68 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 1-year low of $115.66 and a 1-year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). The company had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. Neurocrine Biosciences had a return on equity of 20.49% and a net margin of 21.55%.The business's revenue for the quarter was up 28.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.69 EPS. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 6.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wedbush increased their target price on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an "outperform" rating in a research report on Wednesday. Citigroup raised their target price on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the company a "buy" rating in a research note on Wednesday. Royal Bank Of Canada upped their price target on shares of Neurocrine Biosciences from $176.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday. Leerink Partners raised their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an "outperform" rating in a research report on Wednesday, April 22nd. Finally, Canaccord Genuity Group upped their target price on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a "buy" rating in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $183.00.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Q1 results beat and commercial momentum — Neurocrine reported record Q1 results with revenue and INGREZZA sales above expectations and reaffirmed 2026 guidance; this underpins the bullish reaction from investors. Q1 2026 Financial Results
• Positive Sentiment: Analyst upgrades/price‑target lifts — Several firms raised targets (Citigroup to $246, Piper Sandler to $207, RBC to $180, Wedbush, Guggenheim reaffirmed buy), signaling stronger earnings/visibility and supporting upside sentiment. Benzinga Coverage
• Positive Sentiment: Clinical adoption support for CRENESSITY — Publication of expert recommendations to guide glucocorticoid dose reduction after starting CRENESSITY helps real‑world prescribing and could aid uptake and longer‑term revenue stability. CRENESSITY Recommendations
• Neutral Sentiment: Additional analyst actions — Morgan Stanley boosted its target to $191 but kept an equal‑weight rating (mixed signal), while Guggenheim reaffirmed a $175 target; these provide valuation context but are less directional. Benzinga Analyst Notes
• Neutral Sentiment: Conference and disclosures — Management will present at the BofA Health Care Conference and the company posted the earnings call transcript and slide deck for investors to dig into guidance and pipeline progress. BofA Presentation Earnings Transcript
• Negative Sentiment: Soleno acquisition adds uncertainty — Coverage notes the Soleno deal (acquiring VYKAT XR) brings upside but also integration, regulatory and execution risk that could increase volatility and offset some near‑term confidence. Seeking Alpha: Soleno Deal Analysis

Neurocrine Biosciences Company Profile

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.